Strategic Partnerships Blanver has a track record of forming strategic partnerships with global and regional players in oncology and infectious disease spaces, including recent collaborations with Adalvo and Biophytis. Leverage these relationships to position complementary products, co-development opportunities, and joint go-to-market initiatives in Latin America and beyond.

Expansion in Oncologia Recent activity highlights Blanver’s growing focus on oncology and hematology, with two value-add oncology products in partnership with Adalvo. There is a clear opportunity to propose additional cancer therapeutics and supportive care IPAs, including generics and specialized inputs, for regional markets.

Insumos Farmacêuticos Historically a major excipients producer transitioning to Active Pharmaceutical Ingredients (IFAs) and medicines, Blanver has manufacturing scale in São Paulo and a trajectory toward high-quality drug development. Target collaborations around end-to-end supply of IFAs, contract manufacturing, and formulation support for new or generic therapies.

Public-Private Ties Blanver collaborates with public laboratories for treatments in HIV/AIDS, Hepatitis C, osteoporosis, and CNS diseases. This suggests openness to government tenders and public-sector partnerships for essential medicines and rare diseases, presenting a channel for bid opportunities and co-financed programs.

Global Licensing With licensing activity abroad, including BIO101 from Biophytis and cross-border partnerships, there is a door for international co-development, manufacturing licenses, and regional distribution deals. Develop a pipeline pitch focusing on LATAM market access, regulatory support, and scalable manufacturing capacity.